... Multi-center Trial 多中心试验 OS-Overall Survival 总生存期 PFS- Progression Free Survival 无进展生存期 ...
基于1个网页-相关网页
PFS, rather than overall survival (OS), was accepted by regulatory authorities in the United States and Europe as the endpoint for approval of bevacizumab for the renal cell carcinoma indication.
欧美权威机构接受PFS作为观察终点，而非总生存期（OS），肾细胞癌作为贝伐单抗的适应症范围。
Secondary end points included overall survival (OS) and overall response rate (ORR) per IRC.
次要终点包括IRC评估的总生存期(OS)和总缓解率(ORR)。
The primary endpoint was overall survival (OS).
主要终点是总生存率(OS)。
应用推荐